José Ángel Martinez Escribano

Auropean Ventures, Inc. operates as a private company focused on the exploration and development of gold and polymetallic projects. The firm has projects in Spain, Slovakia and Yukon. The company is headquartered in Carp, Canada.

Portigon AG engages in the management of its own assets. It also provides financial services and conducts banking activities. The company was founded in 1969 and is headquartered in Duesseldorf, Germany.

UNIRISCO Galicia (UNIRISCO) is an independent Spanish venture capital firm which was formed in 2000 as part of a University of Santiago de Compostela initiative to promote the creation of companies making use of technology research emanating from the University of Santiago and the University of Vigo. Based in Santiago de Compostela, UNIRISCO facilitates direct contact between major R&D centres in Galicia, allowing access to the university research groups and their scientific production skills. They also provide investee companies with consultancy services and access to their network of partners.

vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany.

Uninvest SGEIC SA (Uninvest) is a venture capital firm founded in 2005. The firm is headquartered in Santiago de Compostela, Spain.

3i Private Equity is a private equity firm, founded in 1945. The firm is headquartered in London, United Kingdom with additional offices around the world.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Biocontrol Technologies. SL develops and produces microorganisms as pest control agents. The firm offers T-34 Biocontrol product. It services include analysis of pathogen populations, specific seminars for formers and advisers in different fields to improve plant growth. The company was founded by Francesc Peremiquel Lluch in 2004 and is headquartered in Barcelona, Spain.

Immunostep SL develops and manufactures cell reagents. The firms manufacture and commercialization of cell culture reagents for use in flow cytometry diagnosis and clinical research. Its services include polyclonal development, contract services, price list service, monoclonal development, chicken polyclonal development, rabbit polyclonal development. The company was founded by Ricardo Jara Acevedo, Jose Claros Parra and Alfredo Conde Alonso in September 2001 and is headquartered in Salamanca, Spain.

Fort Rock Capital Ltd. provides investment services. The company is headquartered in London, the United Kingdom.

Part of Medinet Topco Ltd., Medinet Midco I Ltd. is a provider of specialised clinical teams that deliver additional elective services to the NHS. The company is based in Sutton Coldfield, UK. Medinet Midco I offers urology and dermatology insourcing services, as well as fully managed specialised clinical teams. The British company was founded in 2016 and has been helping to reduce NHS waiting times for 15 years.

Cleon Capital Advisors SL (Cleon Capital Advisors) is a private equity firm founded in 2015 by Nicola Zambon. The firm is headquartered in Madrid, Spain with additional office in Milan.

Part of Greenhill & Co., Inc., Greenhill & Co. Spain Ltd. is a Spanish company that provides financial advisory services. The company is based in Madrid, Spain.

Part of Medinet Topco Ltd., Medinet Clinical Services Ltd. is a leading provider of specialised clinical teams delivering additional elective services to the NHS. The company is based in Sutton Coldfield, UK. The British company offers fully managed specialised clinical teams to help reduce NHS waiting times throughout the UK, including urology and general surgery insourcing. The company was founded in 2005 with the intention of easing the pressure on the NHS service, so that it can see and treat more patients.

Part of Medinet Topco Ltd., Medinet Midco II Ltd. functions as an investment holding British company. The company is based in Sutton Coldfield, UK and was founded in 2016.

Pregimmune Corp. is a private company based in Dover, DE. The company specializes in developing novel immunotherapies for pregnancy-related complications. The company's research focuses on understanding the immune system's role in pregnancy and developing therapies to prevent or treat complications such as preeclampsia, preterm birth, and fetal growth restriction.